Diaceutics x DeepIntent Partnership: Transforming HCP Engagement with Real-Time Diagnostic Solutions and Genomic Audiences
Patrick Mullaney
We're pleased to announce our partnership with DeepIntent. This collaboration is set to connect life sciences brands with physicians at the exact moment of treatment decision. We are a leading diagnostic solutions provider. Our technology leverages AI-driven diagnostic and genomic data to drive therapy adoption.
Our diagnostically driven audiences will be available on DeepIntent’s industry-leading healthcare demand-side platform (DSP). Life science marketers will gain access to global diagnostics, lab, and genomic insights. They will be able to plan, activate, and optimize their campaigns based on real-world data. Unlike traditional claims-based approaches, our data enables engagement with physicians in real-time. So that data is more precise, reflecting what is happening today, not months in the past.
Media buyers using DeepIntent now have access to over 100 pre-built audience segments.
These include:
- General medicine (such as diabetes, CKD, and cardiovascular disease)
- Biomarker-driven oncology therapies (including EGFR+ NSCLC, HER2+ breast cancer, and PD-L1+ prostate cancer)
- Select rare diseases
These audiences empower marketers to:
- Target HCPs based on a patient’s real clinical journey, from testing to treatment decisions
- Close the recency gap in claims data by activating campaigns on diagnostic and lab triggers
- Uncover hidden treaters not visible in commercial claims datasets but identifiable through diagnostic insights
Scott Phillips, VP, Real World Data at Diaceutics
“In a competitive market, influencing physician behavior depends on timing and context. By partnering with DeepIntent, we’re giving brand and omnichannel teams the ability to act with greater precision. This means reaching physicians in the moment, not after the fact. This is how campaigns become truly impactful.”
Natalie Mancuso, SVP, Data Partnerships at DeepIntent.
"DeepIntent empowers healthcare marketers to achieve their brand goals with differentiated data and pharma-specific real-time optimization. By bringing Diaceutics’ audiences into our Audience Marketplace, we’re enabling clients to reach HCPs with dynamic signals. Connecting at key moments of need to drive stronger engagement, outcomes, and ultimately, better care."
About Diaceutics
Our mission is to allow every patient access to the right test and therapy to positively impact their disease outcome. For 20 years, we've specialized in delivering precision medicine and diagnostic solutions to the world’s top pharma and biotechs. We are bridging the gap between biomarker testing and targeted therapies. And this empowers industry partners to succeed in the evolving field of personalized healthcare.
About DeepIntent
DeepIntent is the leading healthcare demand-side platform (DSP). It has been purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision.
Trusted by the world’s top healthcare brands, DeepIntent unites media, identity, and real-world clinical data. This powers privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent delivers measurable audience quality and script lift at scale.
Learn more heading
We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.
This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more
What is the Diaceutics and DeepIntent partnership?
Diaceutics has partnered with DeepIntent to bring diagnostically driven HCP audiences onto DeepIntent's healthcare demand-side platform (DSP). This gives life science marketers access to global diagnostics, lab and genomic insights, enabling them to plan, activate and optimize campaigns based on real-world data rather than traditional claims-based approaches.
How does diagnostic data improve HCP targeting compared to claims-based data?
Unlike claims data, which can reflect activity from months in the past, diagnostic and lab data enables engagement with physicians in real-time, reflecting what is happening today. This closes the recency gap in claims data by activating campaigns based on diagnostic and lab triggers at the moment of treatment decision.
What HCP audience segments are available through the Diaceutics and DeepIntent partnership?
Media buyers using DeepIntent now have access to over 100 pre-built audience segments, covering general medicine (such as diabetes, CKD and cardiovascular disease), biomarker-driven oncology therapies (including EGFR+ NSCLC, HER2+ breast cancer and PD-L1+ prostate cancer), and select rare diseases.
How can diagnostic data help identify hidden treaters not visible in claims data?
Diagnostic insights can uncover physicians who are actively treating relevant patients but who don't appear in commercial claims datasets. This allows brands to reach a fuller population of relevant HCPs based on real diagnostic and lab activity, rather than relying solely on historical billing data.
Why does timing matter in physician engagement for life sciences marketing?
Influencing physician behaviour depends on reaching them at the right moment, ideally during the actual treatment decision window, rather than after the fact. As Scott Phillips, VP of Real World Data at Diaceutics, notes, partnering with DeepIntent gives brand and omnichannel teams the ability to act with greater precision and timing.
How does this partnership benefit pharma and biotech marketing teams?
Written By Patrick Mullaney
Newsletter sign up
READY TO DO COMMERCIALIZATION DIFFERENTLY?
You might also be interested in?
Amplifying Your Precision Medicine Strategy: The role of Engagement Experts and Peer Networks
Enhance your precision medicine strategy through multi-modal communications and peer engagement, driving effective diagnostic commercialization and maximizing patient outcomes.